Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa

This article was originally published in The Pink Sheet Daily

Executive Summary

The CHMP has recommended Bydureon for authorization, despite reservations having been expressed by FDA. An additional indication for Pradaxa was also recommended, boosting the drug's profile as a potential blockbuster.

You may also be interested in...



German Reimbursement Assessment Process Fells Third Rx Victim

Lilly/Boehringer's Trajenta will not be marketed in Germany, as companies feel it will not meet the criteria set by authorities to get the reimbursement level it deserves.

German Reimbursement Assessment Process Fells Third Rx Victim

Lilly/Boehringer's Trajenta will not be marketed in Germany, as companies feel it will not meet the criteria set by authorities to get the reimbursement level it deserves.

In Seeking Focus, Ipsen Turns To Specialty Pharma Model

Marc de Garidel, Ipsen’s new CEO, is re-focusing the mid-sized French group’s attention on its core commercial assets, trimming the portfolio, and narrowing down early-stage R&D. The de-risking move turns Ipsen sharply in a specialty pharma direction that may please some investors over the near-term, but which raises questions related to the future viability of Ipsen’s R&D engine.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072110

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel